Ashley Divers, NP
Gerontology · Camden, SCNPI 1023407269
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,088 and has fallen 90.6% since, to $102 in 2025.
Across 84 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$232
- AstraZeneca$197
- AbbVie$181
- Cvrx, Inc.$136
- Abbott$117
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$106
- plus $610 from 19 others
What the payments were for
- Food & beverage$1,580100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $232 |
| AstraZeneca | 8 | $197 |
| AbbVie | 18 | $181 |
| Cvrx, Inc. | 1 | $136 |
| Abbott | 1 | $117 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $106 |
| Teva Pharmaceuticals USA, Inc. | 6 | $101 |
| Amgen | 4 | $66 |
| Johnson & Johnson | 3 | $65 |
| Amarin Pharma, Inc. | 4 | $52 |
| GSK | 3 | $41 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Merck | 2 | $34 |
| Medtronic | 1 | $28 |
| Boehringer Ingelheim | 2 | $24 |
| Pfizer | 2 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Novartis | 1 | $13 |
| Astellas Pharma US Inc | 1 | $12 |
| Seqirus USA Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$136
- FREESTYLE LIBRE 3$117
- Ozempic$102
How this compares
$1,580 in reported general payments places this provider in the 60th percentile of 137 gerontology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 116 | $139,094 |
| OzempicSemaglutide | 72 | $92,607 |
| TrulicityDulaglutide | 68 | $78,952 |
| EliquisApixaban | 60 | $63,188 |
| JardianceEmpagliflozin | 57 | $50,803 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $46,982 |
| JanuviaSitagliptin Phosphate | 40 | $29,203 |
| FarxigaDapagliflozin Propanediol | 20 | $19,229 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $15,338 |
| MyrbetriqMirabegron | 28 | $13,145 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $8,848 |
| Dexlansoprazole DrDexlansoprazole | 18 | $5,353 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,177 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 127 | $4,885 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $3,828 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $232 | $92,60772 claims |
| PfizerEliquis | $23 | $63,18860 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $41 | $62,32068 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $24 | $55,98068 claims |
| MerckJanuvia | $34 | $29,20340 claims |
| AstraZenecaFarxiga, Symbicort | $197 | $23,05732 claims |
| Astellas Pharma US IncMyrbetriq | $12 | $13,14528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 137 gerontology providers in South Carolina.
Other gerontology in Camden
- Jennifer StokesCamden$4K
- Timothy MalinowskiGreenville$49K
- Ann ShattuckNorth Charleston$15K
- Erin SullivanColumbia$13K
- Nicole FerroniCharleston$11K
- Kathryn RarickGreenville$10K
- Ryan BakerColumbia$9K
- Rachael WillsGreenville$8K
- Karen CainGreenville$8K
- Emily KachelmeyerSummerville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.